Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Competitive Generic Therapy Designations Growing Despite Lack Of Guidance

Executive Summary

US FDA developing document describing program operations, but that has not stopped sponsors from requesting and receiving the breakthrough-like designation. 

You may also be interested in...



Let's Get Real – ANDA Approval Likely Takes More Than Two Years, US FDA Says

Office of Generic Drugs Director Kathleen Uhl calls a two-cycle approval timeline a realistic expectation for ANDA approval, but would not say that most ANDAs will fall into the paradigm.

New ANDA Review Pathways: Should You Be A Priority Or Expedited?

Amid confusion about multiple priority and expedited pathways for US generic drug applications, industry asks which are a true advantage.

Breakthrough-Style Program For ANDAs Added To House User Fee Bill

Energy and Commerce subcommittee unanimously advances reauthorization legislation with four added amendments, including one that would allow for certain generic sponsors to meet early and often with FDA to speed development.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB002489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel